Merck KGaA Aktie
Signale Merck KGaA
Signale
Formationen
Derivate Merck KGaA
Nachrichten Merck KGaA
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reportsDrugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its |
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugsInvestors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with |
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?Merck has an attractive yield and a long history of dividend growth. |
Merck: Why Investors Should Remain Bullish Despite Patent Risks |
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt |
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent |
Pharmabranche: Sanofi trennt sich von CEO – scheidende Merck-Chefin Garijo übernimmtNach 15 Jahren beim deutschen Pharmakonzern Merck wechselt Belén Garijo zum französischen Konkurrenten Sanofi. Der Vertrag ihres Vorgängers wird nicht |
Exelixis (EXEL) Q4 2025 Earnings Call TranscriptImage source: The Motley Fool.DateTuesday, February 10, 2026 at 5:00 p.m. ETCall participantsPresident and Chief Executive Officer — Michael MorrisseyChief |